2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1729

Increased Serum Levels of Micro-RNA 30d and Micro-RNA 423-5p in 2 Independent Cohorts of Patients with Morphea
Abstract Number: 1071

Increased Susceptibility of SLE-Prone Mice to Pulmonary Haemophilus Influenzae Infection Was Attributed to Dysfunctions of Innate Immune Responses
Abstract Number: 2644

Increased Toll-like Receptor 7 Expression Promotes B Cell Abnormalities and Skewing of Cytokine and Autoantibody Profiles in SLE Patients
Abstract Number: 549

Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
Abstract Number: 1095

Increasing Lipid Panel Monitoring in a Rheumatology Clinic
Abstract Number: 994

Increasing Population Burden of Psoriatic Disease in Ontario, Canada – a Longitudinal Cohort Study
Abstract Number: 199

Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study
Abstract Number: 1293

Indications for Cesarean Delivery in Systemic Lupus Erythematosus Pregnancies
Abstract Number: 1641

Indications for Initial Renal Biopsy in Systemic Lupus Erythematosus: A Systematic Review of the Literature
Abstract Number: 2289

Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis
Abstract Number: 2638

Inducible cAMP Early Repressor Promotes Glycolysis By Inhibiting the Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 2 in Th17 Cells
Abstract Number: 388

Induction of Anti-Citrullinated Protein Antibodies By Peptidyl Arginine Deiminase Immunization: A New Model for the Development of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
Abstract Number: 1462

Induction of Immune Tolerance through an Epitope-Specific Vaccine Induces Clinical Amelioration in Patients with Rheumatoid Arthritis
Abstract Number: 2603

Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Abstract Number: 1542

Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].